Latife Arzu ARAL, Resul KARAKUŞ, Cemalettin AYBAY, Bilkay BAŞTÜRK

Hepatit B virus (HBV) yüzey antijejeninin (HBsAg) ölçümü amacı ile yüksek düzeyde hassas bir ELISA kitinin geliştirilmesi

Background: Hepatitis B Virus (HBV) infection is of global importance and many studies are aimed to develop more sensitive diagnostic tools and improve therapeutic options. HBV infection is diagnosed and followed-up basically by serological studies, among which the enzyme-linked immunosorbent assay (ELISA) is widely used. Aim: To develop a sensitive HBsAg ELISA for both research and diagnostic purposes. Materials and Methods: A hybridoma (clone 4D1) secreting anti-HBs IgG2a monoclonal antibody (mAb) was used for the establishment of our in-house ELISA. Tests were performed for both cell culture medium and human sera. The hepatoma cell lines of human origin PLC/PRF/5 and Hep G2 were used for validation assays. Tests for human sera were run concurrently with the Access® Immunoassay System. Results: The in-house ELISA system had an analytical sensitivity less than 0.41 ng/ml for both human sera and cell culture medium. The performance comparison of our in-house ELISA system with the Access® Immunoassay System even for samples with s/co levels of 1.5-13.7 gave a significant correlation. Conclusions: These reliable results of the newly established HBsAg ELISA system make it a promising candidate for diagnostic as well as research purposes.

Development of a highly sensitive ELISAfor quantification of hepatitis B virus (HBV) surface antigen ( HBsAg)

PDF

___

1. Alter MJ. Epidemiology of hepatitis B in Europe and worldwide. J Hepatol 2003; 39 (Suppl 1): S64-69.
2. Custer B, Sullivan SD, Hazlet TK, Iloeje U, Veenstra DL, Kowdley KV. Global epidemiology of hepatitis B virus. J Clin Gastroenterol 2004; 38 (Suppl): S158-168.
3. Joller-Jemelka HI, Pfister HF, Grob PJ. The prognostic significance of quantitative HBsAG determination in acute hepatitis B. Schweiz Med Wochenschr 1985; 115: 1249-1256.
4. Frosner GG, Schomerus H, Wiedmann KH, Zachoval R, Bayerl B, Backer U et al. Diagnostic significance of quantitative determination of hepatitis B surface antigen in acute and chronic hepatitis B infection. Eur J Clin Microbiol 1982; 1: 52-58.
5. Biswas R, Tabor E, Hsia CC, Wright DJ, Laycock ME, Fiebig EW et al. Comparative sensitivity of HBV NATs and HBsAg assays for detection of acute HBV infection. Transfusion 2003; 43: 788-798.
6. Aybay C, Imir T. Development of a rapid, single-step procedure using protein G affinity chromatography to deplete fetal calf serum of its IgG and to isolate murine IgG1 monoclonal antibodies from supernatants of hybridoma cells. J Immunol Methods 2000;233: 77-81.
7. Weber B, Bayer A, Kirch P, Schluter V, Schlieper D, Melchior W. Improved detection of hepatitis B virus surface antigen by a new rapid automated assay. J Clin Microbiol 1999; 37: 2639-2647.
8. Hatzakis A, Magiorkinis E, Haida C. HBV virological assessment. J Hepatol 2006; 44 (1 Suppl): S71-76.
9. Daemer RJ, Feinstone SM, Alexander JJ, Tully JG, London WT, Wong DC et al. PLC/PRF/5 (Alexander) hepatoma cell line: further characterization and studies of infectivity. Infect Immun 1980;30: 607-611.
10. Deml L, Wolf H, Wagner R. High level expression of hepatitis B virus surface antigen in stably transfected Drosophila Schneider-2 cells. J Virol Methods 1999; 79: 191-203.
11. Wu J, Gerber MA. The inhibitory effects of antisense RNA on hepatitis B virus surface antigen synthesis. J Gen Virol 1997; 78:641-647.
12. Walory J, Grzesiowski P, Hryniewicz W. Comparison of four serological methods for the detection of diphtheria anti-toxin antibody. J Immunol Methods 2000; 245: 55-65.
13. Kosters K, Riffelmann M, Dohrn B, von Konig CH. Comparison of five commercial enzyme-linked immunosorbent assays for detection of antibodies to Bordetella pertussis. Clin Diagn Lab Immunol 2000; 7: 422-426.
14. Kuhns MC, Kleinman SH, McNamara AL, Rawal B, Glynn S, Busch MP et al. Lack of correlation between HBsAg and HBV DNA levels in blood donors who test positive for HBsAg and anti-HBc: implications for future HBV screening policy. Transfusion 2004; 44: 1332-1339.